- Home
- LCNB vs TARA Comparison
LCNB vs TARA Comparison
Compare LCNB & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LCNB | TARA |
|---|---|---|
| Founded | 1877 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 236.1M |
| IPO Year | 1999 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LCNB | TARA |
|---|---|---|
| Price | $20.35 | $4.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.40 |
| AVG Volume (30 Days) | 33.9K | ★ 644.4K |
| Earning Date | 04-22-2026 | 05-01-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 68.04 | 38.25 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $6,445,000.00 | $2,948,000.00 |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $65.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.11 | $2.97 |
| 52 Week High | $20.62 | $7.82 |
Technical Indicators
Market Signals| Indicator | LCNB | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 68.72 | 46.50 |
| Support Level | $15.53 | $3.69 |
| Resistance Level | $20.62 | $4.23 |
| Average True Range (ATR) | 0.79 | 0.15 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 90.34 | 27.91 |
Price Performance
Historical ComparisonAbout LCNB LCNB Corporation
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.